BIO-key Posts $4.01 Per-Share Q3 Loss
BKYI sits 73% above its 52-week low of $1.55.
Summary
BIO-key reported a third-quarter loss of $4.01 per share on revenue of $1.48M, with license fees up 39% while revenue fell 4%. The company is a micro-cap trading at $2.68, so a per-share loss of that size is outsized relative to the share price and points to heavy dilution from the warrant and debt-for-equity activity that has dominated recent filings. That dilution theme runs through the timeline: the October 2 8-K exchanged $416,315.80 of secured debt for 247,805 shares, and the October 30 filings registered up to 1,236,668 Armistice warrant shares for resale.
At the time of this announcement, BKYI was trading at $2.68 on NASDAQ in the Technology sector, with a market capitalization of approximately $5.3M. The 52-week trading range was $1.55 to $11.10. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.